IL33 and atopic eczema: Biologics targeting IL-33 (e.g., Etokimab, Tozorakimab) have entered testing in atopic dermatitis, with early proof-of-concept data suggesting reduced disease activity and pruritus, including a significant reduction in neutrophil skin infiltrates [138].